Otcbb TPIM Thread

[Stock_Analyzer]

Looking for a possible breakout here. Resistance at .27 200 MA line then .33 .46 .70 ahead. Support at .23 .20 below. A break of the wedge below gets this stock rolling.

TPIM - SharpCharts from StockCharts.com

[Stock_Analyzer]

Closed at .31 on 260k shares today. Looking for that .33 break early next week hopefully.

[Stock_Analyzer]

About TapImmune Inc (TPIM.OB)

TapImmune Inc.

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company's vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or �accelerant' to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010.

Patented medical technology forges a new frontier in cancer therapy


ABC News, Business Week, and Popular Mechanics cover new
technology that turns the body's natural defenses against
cancer and infectious pathogens


New technology turns the body's natural defenses against cancer
and infectious pathogens


Patented cancer therapy has multiple applications in
$13 billion vaccine market


Proof of concept demonstrated - 70% of subjects in study with
small cell carcinomas remained tumor free


$6 billion market by 2010 with 70% CAGR (Compound Annual Growth Rate)


Early preclinical success validates patented
cancer therapy

[EricHair]

I wasn't an active trader when Genemax (GMXX) was big, but it looks like I'll get a second chance. From what I've read, Genemax (now TapImmune), was a huge scam of the pump and dump variety. Supposedly they've cleaned out their closets and tossed the rifraf, but can a name change really do all that.

Traders beware.

SA, how about some words of caution regarding this call huh?

[Stock_Analyzer]

If I looked up all the stocks I post then I would be here for ages, thats why I always put in my signature to check each stock, do your own DD and only buy and sell if YOU want to. To me TPIM was a "Chart" play as it broke the wedge we talked about PRE MARKET in chat on friday (Watch list Room). Now for me, I never hold a stock more than a day or two (always a exception) so dont ever marry the stocks and if it starts to go south then I just sell.

Originally Posted by EricHair

I wasn't an active trader when Genemax (GMXX) was big, but it looks like I'll get a second chance. From what I've read, Genemax (now TapImmune), was a huge scam of the pump and dump variety. Supposedly they've cleaned out their closets and tossed the rifraf, but can a name change really do all that.

Traders beware.

SA, how about some words of caution regarding this call huh?

[Stock_Analyzer]

Published Third Party, Independent Research Corroborates Promise of TAP Cancer Therapeutic as a Therapy for the Treatment of Cancer
Monday June 2, 9:00 am ET


VANCOUVER, BC--(MARKET WIRE)--Jun 2, 2008 -- TapImmune Inc. (OTC BB:TPIM.OB - News), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced that an independent third party research article in the Journal of Investigative Dermatology has confirmed and corroborated that a TAP incorporated vaccine should be considered as a therapy for the treatment of cancer, in this case, Melanoma.
ADVERTISEMENT


The article, in advance online publication 3 April 2008, titled, "Restoration of the Expression of Transporters Associated with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity," is yet another promising research study that confirms and corroborates the TAP incorporated vaccine. There is now a vast amount of research data supporting and corroborating the initial description of the promising effect of TAP as a cancer therapy and their effect on tumor recognition.

TapImmune patented this novel cancer treatment in 2002 and has been developing it for clinical evaluation. This year it is our intention to bring all this work and research forward by initiating our first cGMP vaccine manufacturing contract. This will enable us to initiate toxicology testing and begin protocol design for a First-In-Man trial (phase 1). Updates are available on our website, so please visit TapImmune Inc. and sign up for additional news alerts.

To read the full article referenced in this release please visit Journal of Investigative Dermatology - Restoration of the Expression of Transports Associated with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity

About TapImmune

TapImmune is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, TAP vaccine, performs a key step in moving characteristic markers called antigens to the surfaces of cells. TAP, or Transporters Associated with Antigen Processing, are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected.

The Company's vaccine has shown, in preclinical tests, effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or 'accelerant' to enhance targeted vaccines against infectious diseases. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010.

TapImmune is preparing GLP manufactured materials for the commencement of toxicology studies on the AdhTAP vaccine, leading to the initiation of a Phase I clinical trial. The Company is also developing a TAP-based vaccine adjuvant which existing preclinical data suggest increases the efficacy of targeted prophylactic vaccines by up to 1000 times.

Additional information on the Company can be found on its web site TapImmune Inc.

Safe Harbor Statement

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-KSB and other SEC filings which are available through EDGAR at U.S. Securities and Exchange Commission (Home Page). These are among the primary risks we foresee at the present time. The Company assumes no obligation to update the forward-looking statements.



Contact:
Contact for this Press Release:
Denis Corin
TapImmune Inc.
604 264 8274



--------------------------------------------------------------------------------
Source: TapImmune Inc.

[EricHair]

Originally Posted by Stock_Analyzer

If I looked up all the stocks I post then I would be here for ages, thats why I always put in my signature to check each stock, do your own DD and only buy and sell if YOU want to. To me TPIM was a "Chart" play as it broke the wedge we talked about PRE MARKET in chat on friday (Watch list Room). Now for me, I never hold a stock more than a day or two (always a exception) so dont ever marry the stocks and if it starts to go south then I just sell.

That's true. I apologize for making it sound like you need to check the entire back history of every play. It was a great play and I wish I knew more about drawing trendlines and patterns.

Cheers

[Stock_Analyzer]

No need to apologize my friend. Some of these plays work out and then sometimes they dont, but every bit of DD helps!!

Originally Posted by EricHair

That's true. I apologize for making it sound like you need to check the entire back history of every play. It was a great play and I wish I knew more about drawing trendlines and patterns.

Cheers

[Stock_Analyzer]

covered our gap that we called in our alerts to .30 and now hit .40 today, still watching.